EGFR and neoplasm: Pyrotinib is an irreversible pan-HER inhibitor independently developed in China, which permanently binds to the ATP-binding sites of EGFR/HER1, HER2, and HER4 to block dimerization and downstream signaling, thereby inhibiting tumor growth.